Resverlogix Announces Voting Results

TSX Exchange Symbol: RVX

CALGARY, Oct. 3, 2013 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual and special meeting of shareholders held on October 3, 2013, each of the six nominees proposed as a director and listed in its management information circular dated August 21, 2013 (the "Information Circular") were elected as directors. Proxy voting results for each nominee are set out below.

  Votes For Votes Withheld % For % Withheld
Donald J McCaffrey 32,555,972 142,114 99.57% 0.43%
Peter Johann 32,587,972 108,783 99.67% 0.33%
Kelly McNeill 32,565,972 130,783 99.60% 0.40%
Arthur Higgins 32,592,512 104,243 99.68% 0.32%
Kenneth Zuerblis 32,589,072 107,683 99.67% 0.33%
Eldon Smith 32,598,772 97,983 99.70% 0.30%

At the meeting, shareholders were also asked to consider a resolution to approve anti-dilution adjustment provisions contained in certain outstanding common share purchase warrants of the Corporation, as more particularly described in the Information Circular. The warrant adjustment resolution failed to obtain approval from shareholders.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on our blog at

Company Contacts:
Donald J. McCaffrey    Kenneth Lebioda
President and CEO     SVP Business & Corporate Development
Resverlogix Corp.    Resverlogix Corp.
Phone: 403-254-9252    Phone: 403-254-9252
Email:   Email:


SOURCE: Resverlogix Corp.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890